How to Obtain Appropriate Type 2 Diabetes Control in the First 180 Days of Treatment Initiation

References

• . Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Venkat Narayan KM. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002;136(8):565–574
   PubMed Web of Science ®Google Scholar
• . Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association Clinical Practice Recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29(3):531–537
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9(3):213–217
   PubMed Web of Science ®Google Scholar
• . Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27(7):1535–1540
   PubMed Web of Science ®Google Scholar
• . Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007;22(4):453–458
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO, ; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–192
   PubMed Web of Science ®Google Scholar
• . Colagiuri S, Cull CA, Holman RR; UKPDS Group.Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. Prospective Diabetes Study 61. Diabetes Care. 2002;25(8):1410–1417
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–549
   PubMed Web of Science ®Google Scholar
• . Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res. 1996;28(9):426–429
   PubMed Web of Science ®Google Scholar
• . Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group. Diabetes Care. 1997;20(4):597–606
   PubMed Web of Science ®Google Scholar
• . Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; Rosiglitazone Clinical Trials Study Group.Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):280–288
   PubMed Web of Science ®Google Scholar
• . Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605–1611
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Hassman DR, Madder RD, ; Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004;27(6):1265–1270
   PubMed Web of Science ®Google Scholar
• . Jovanovic L, Dailey G III, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol. 2000;40(1):49–57
   PubMed Web of Science ®Google Scholar
• . Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632–2637
   PubMed Web of Science ®Google Scholar
• . Kim D, Macconell L, Zhuang D, . Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487–1493
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators.The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29(3):554–559
   PubMed Web of Science ®Google Scholar
• . Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care. 2002;25(10):1685–1690
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Bloomgarden ZT, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6):1282–1288
   PubMed Web of Science ®Google Scholar
• . Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med. 2006;145(2):125–134
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269–1274
   PubMed Web of Science ®Google Scholar
• . Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007;27(4):279–285
   PubMed Web of Science ®Google Scholar
• . Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9(3):418–427
   PubMed Web of Science ®Google Scholar
• . Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, Garber AJ. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med. 2007;18(1):56–62
   PubMed Web of Science ®Google Scholar
• . Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–259
   PubMed Web of Science ®Google Scholar
• . Dailey G. A timely transition to insulin: identifying type 2 diabetes patients failing oral therapy. Formulary. 2005;40(4):114–130
   Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; for the Exenatide-113 Clinical Study Group.Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Burger J, Johns D, . Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29(11):2333–2348
   PubMed Web of Science ®Google Scholar
• . Vilsbøll T, Zdravkovic M, Le-Thi T, . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608–1610
   PubMed Web of Science ®Google Scholar
• . Herman GA, Stevens C, Van Dyck K, . Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–688
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators.Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Hissa MN, Garber AJ, ; for the Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Hollander P, Li J, Allen E, Chen R; for the CV181-013 Investigators.Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810–4819
   PubMed Web of Science ®Google Scholar
• . Riddle M, Frias J, Zhang B, . Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30(11):2794–2799
   PubMed Web of Science ®Google Scholar
• . Murata GH, Hoffman RM, Duckworth WC, Wendel CS, Shah JH. Contributions of weekly mean blood glucose values to hemoglobin A1c in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Am J Med Sci. 2004;327(6):319–323
   PubMed Web of Science ®Google Scholar
• . Osterweil N. EASD: average blood glucose reflects real life glycemia. http://www.medpagetoday.com/MeetingCoverage/EASD/6711. Accessed March 16, 2010
   Google Scholar
• . Phillips LS, Branch WT, Cook CB, . Clinical inertia. Ann Intern Med. 2001;135(9):825–834
   PubMed Web of Science ®Google Scholar
• . Davis RM, Wagner EH, Groves T. Managing chronic disease. BMJ. 1999;318(7191):1090–1091
   PubMedGoogle Scholar
• . Yusuf HR, Giles WH, Croft JB, Anda RF, Casper ML. Impact of multiple risk factor profiles on determining cardiovascular disease risk. Prev Med. 1998;27(1):1–9
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens. 2001;14(3):286–292
   PubMed Web of Science ®Google Scholar
• . Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep. 2002;4(5):343–349
   PubMed Web of Science ®Google Scholar
• . National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 express. Bethesda, MD: US Department of Health and Human Services; 2004. NIH publication No. 04-5230. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Accessed March 16, 2010
   Google Scholar